Concept of Operations (ConOps) — ISO/IEC/IEEE 15289 — Description | IEEE 29148 §6.1
Generated 2026-03-27 — UHT Journal / universalhex.org
The Pharmaceutical Manufacturing Line exists to produce oral solid dosage forms (tablets and capsules) at commercial scale with guaranteed potency, purity, and consistency. Without this system, patients receive medications with variable quality — potentially sub-therapeutic doses or toxic impurities. The operational driver is the transition from traditional batch manufacturing (with weeks-long quality release cycles) to continuous manufacturing with real-time release testing, reducing time-to-patient from 60+ days to under 7 days while maintaining or improving product quality. The system must satisfy regulatory requirements from FDA, EMA, and national authorities across multiple markets, enabling a single manufacturing line to supply global demand for a given product.
| Stakeholder | Relationship | Hex Code |
|---|---|---|
| Production Supervisor | primary line operator, initiates/manages batch records, authorises production decisions (from Normal Production and Degraded scenarios) | 018D5AF9 |
| Quality Control Analyst | monitors PAT data, performs lab testing, sampling, cleaning validation analysis (from all production and changeover scenarios) | 008D3AF9 |
| Maintenance Technician | performs equipment repair, tooling changes, calibration, LOTO procedures (from Tablet Press Jam and Maintenance scenarios) | — |
| Regulatory Inspector (FDA/EMA) | audits manufacturing compliance, reviews data integrity, batch records, validation — not in daily operations but drives all design requirements | — |
| Patient | ultimate beneficiary, no direct system interaction but drives all quality/safety requirements — product quality specifications are proxies for patient safety | — |
| EHS Officer | manages occupational safety, containment strategy, exposure monitoring, emergency response (from Containment Breach Emergency scenario) | — |
| Material Handler | receives, verifies, and dispenses raw materials to production line (from Normal Production scenario) | — |
| Mode | Description |
|---|---|
| Startup/Qualification | triggered by new installation, major equipment change, or periodic requalification schedule → operators execute IQ/OQ/PQ protocols, calibrate instruments, validate cleaning procedures, confirm environmental classification → exits when QA approves all qualification records and line is released for commercial production |
| Normal Production | entry when line is qualified, batch record initiated, raw materials verified and released → continuous manufacturing with PAT monitoring, real-time release testing, automated in-process controls → exits at batch completion, scheduled changeover, or escalation to degraded/emergency mode |
| Degraded Production | entry when non-critical equipment fault detected but product quality can still be assured → production continues at reduced throughput or with manual substitution for failed automated controls, increased sampling frequency, QA notified → exits when fault is repaired (return to Normal) or quality assurance is lost (escalate to Emergency Stop) |
| Changeover/Cleaning | entry at campaign completion or product change → operators execute validated cleaning procedures, perform swab/rinse sampling, HPLC analysis confirms residue levels below acceptance criteria → exits when QC releases equipment as clean and next batch record is initiated |
| Emergency Stop | entry on containment breach, dust explosion risk, cleanroom failure, critical quality system failure, or manual E-stop → all equipment de-energises, containment systems activate, HVAC to exhaust mode, batch quarantined → exits only after root cause investigation, corrective action, and QA/safety sign-off to restart |
| Maintenance | entry on scheduled maintenance window or corrective maintenance need → equipment isolated via LOTO, maintenance performed per SOPs, calibrations executed against traceable standards, activities logged in CMMS → exits when maintenance complete, equipment re-qualified if needed, and production release authorised |
Production Supervisor initiates batch record at 06:00 for 500mg ibuprofen tablets. Material Handler scans and verifies raw materials (API and excipients) against bill of materials using barcode/RFID. Materials are dispensed in the weigh booth under laminar flow. Granulation Operator loads blender, executes wet granulation program (15min blend, fluid bed drying to <2% LOD). Compression Operator starts rotary press at 60 RPM, PAT system (NIR probe) monitors content uniformity in real-time, tablet weight/hardness checks every 15 minutes auto-sampled. QC Analyst reviews real-time PAT data on SCADA dashboard, confirms dissolution prediction model is within control limits. Coating Operator runs film-coating in pan coater (45min cycle, inlet air 60°C). Packaging Operator runs blister packaging line with vision inspection and serialisation (unique 2D code per unit, aggregation to case/pallet). QA Manager reviews electronic batch record, applies real-time release if all PAT data within specification. Campaign runs 3 days, 6 batches. Changeover cleaning follows.
During mid-campaign production at 14:00, NIR content uniformity probe triggers a system suitability alert — prediction residuals exceed control limit. QC Analyst investigates: reference standard check shows 3% drift in API peak. Analyst notifies Production Supervisor. System automatically increases manual sampling frequency from every 30min to every 10min. Traditional HPLC analysis confirms tablets are within specification. Production continues at 70% throughput to allow manual sampling to keep pace. PAT Engineer recalibrates probe using fresh reference tablets during a planned 30min break in compression. System suitability passes. Normal PAT monitoring resumes. QA reviews deviation record, assesses product made during degraded period — HPLC results confirm all units within specification, no batch impact.
At 10:30 during production of a potent compound (OEL 0.5µg/m³), the continuous air monitoring system in the compression room detects API concentration at 0.8µg/m³ — above the action limit. Alarm sounds. Emergency Stop activates automatically: tablet press de-energises, material transfer valves close, room HVAC switches to 100% exhaust through HEPA. Operators evacuate to the adjacent gowning room within 60 seconds per emergency SOP. EHS Officer dons supplied-air respirator and enters to investigate. Root cause: split in containment transfer sleeve between IBC and press hopper. Maintenance seals the transfer connection. Industrial hygiene performs surface wipe sampling (acceptance: <0.05µg/100cm²). Air monitoring runs for 30 minutes to confirm clearance. Affected batch (200kg granulate in hopper) is quarantined. Operators undergo health monitoring. QA opens major deviation. Production does not resume until corrective action complete — estimated 8-hour downtime.
At 22:00 on night shift, rotary tablet press triggers high-torque alarm and automatically stops. Night Shift Operator observes upper punch stuck in die — likely a broken punch tip lodged in the die bore. Operator follows lockout/tagout SOP: isolates main drive, applies personal lock, verifies zero energy state. Maintenance Technician removes damaged tooling station, extracts metal fragment, inspects adjacent stations for damage. QC performs metal detection check on tablets produced in the last 15 minutes before the jam (metal detector had not alarmed, but precautionary check per SOP). 3 stations show scoring — tooling set replaced. Press restart requires die table inspection, test compression of 50 tablets, weight/hardness verification. Total downtime: 90 minutes. Deviation logged. Batch review determines affected tablets (approximately 2,000 units from scored stations) are segregated and rejected. Batch proceeds with remaining good product.
After completing a methotrexate (cytotoxic, OEL 0.03µg/m³) campaign, the line must be cleaned for ibuprofen production. Cleaning Operator executes the cytotoxic cleaning SOP — a 3-wash cycle: detergent wash at 65°C, alkaline wash at pH 12, purified water rinse. All product-contact surfaces are swab-sampled at 15 predefined worst-case locations (identified during cleaning validation: compression roll gap, hopper weld seams, transfer chute dead-legs). QC Analyst runs HPLC analysis on swab extracts — acceptance limit is 0.004µg/cm² (derived from 1/1000th of minimum therapeutic dose of methotrexate per maximum daily dose of ibuprofen, divided by shared equipment surface area). Rinse water samples analysed for TOC (<10ppm) and conductivity (<1.3µS/cm). First changeover attempt: location 7 (hopper weld seam) fails at 0.008µg/cm². Cleaning Operator repeats localised cleaning with manual scrubbing. Re-sample passes. Total changeover time: 16 hours. QC releases equipment, next batch record initiated.
| Category | Constraint |
|---|---|
| Physical | ISO Class 7/8 cleanroom, 18-25°C ±2°C, 30-65% RH, +15Pa differential pressure, 20 ACH with HEPA filtration, continuous particle/environmental monitoring |
| Regulatory | FDA 21 CFR 210/211/11, EU GMP Annex 15, ICH Q8-Q12, ISPE GAMP 5, ATEX Directive 2014/34/EU for dust explosion zones, IEC 62443 for industrial cybersecurity |
| Power | 480V 3-phase for major equipment (tablet press 30kW, coating pan 50kW, HVAC 200kW), UPS for SCADA/MES/PAT systems (30min ride-through minimum), emergency generator for HVAC and containment systems |
| Network | segregated OT network (ISA/IEC 62443 zones and conduits), air-gapped PLC networks, MES/ERP integration via DMZ, 21 CFR Part 11 compliant user authentication, audit trail on all GxP systems |
| Operational | 16-24 hour production days, 2-3 shift operation, campaign length 3-14 days, changeover 8-24 hours, annual shutdown 2-4 weeks for major maintenance, target OEE >70% |
| System | Interface | Hex Code |
|---|---|---|
| ERP System (SAP/Oracle) | production orders and BOM inbound, batch records and consumption outbound, OPC-UA/REST via DMZ, owned by corporate IT, 99.5% availability | — |
| LIMS | sample requests outbound, test results and disposition inbound, HL7/REST API, owned by QC laboratory, critical for batch release decisions | — |
| Building Utilities | HVAC (conditioned air supply/return), purified water (USP), compressed air (ISO 8573-1 Class 1.2.1), nitrogen, clean steam — shared infrastructure, utility department owned | — |
| Serialisation System | serial number requests outbound, unique identifiers inbound, EPCIS events uploaded to national registries, EU FMD/US DSCSA compliance, supply chain owned | — |
flowchart TB n0["system<br>Pharmaceutical Manufacturing Line"] n1["actor<br>Production Supervisor"] n2["actor<br>QC Analyst"] n3["actor<br>Maintenance Technician"] n4["actor<br>EHS Officer"] n5["actor<br>Material Handler"] n6["actor<br>Regulatory Inspector"] n7["system<br>ERP System"] n8["system<br>LIMS"] n9["system<br>Building Utilities"] n10["system<br>Serialisation System"] n11["actor<br>Patient"] n0 -->|batch records and consumption outbound| n7 n7 -->|production orders and BOM inbound| n0 n0 -->|sample requests outbound| n8 n8 -->|test results and disposition inbound| n0 n9 -->|HVAC purified water compressed air nitrogen| n0 n0 -->|EPCIS events and serial number requests| n10 n10 -->|unique identifiers inbound| n0 n1 -->|batch release decisions and production control| n0 n2 -->|in-process and release testing| n0 n3 -->|maintenance and LOTO procedures| n0 n4 -->|EHS oversight and incident reporting| n0 n5 -->|raw material dispensing and transfer| n0 n6 -->|GMP audit and 21 CFR Part 11 inspection| n0 n0 -->|finished pharmaceutical product| n11
Pharmaceutical Manufacturing Line — Context